A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life
NCT ID: NCT02354105
Last Updated: 2019-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
680 participants
OBSERVATIONAL
2015-01-12
2018-03-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
NCT02552212
Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo
NCT02505542
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
NCT01087762
A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
NCT03215277
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
NCT04436640
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CZP treatment
axSpA patients who have been newly prescribed Certolizumab Pegol (CZP).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient must have a clinical diagnosis of active axial spondyloarthritis (axSpA), \[ankylosing spondylitis (AS) or nonradiographic axial spondyloarthritis (nr-axSpA)\] according to the diagnostic criteria used by the physician in routine clinical practice.
* The decision to prescribe Certolizumab Pegol (CZP) is made by the physician independent of the patient's participation in the NIS.
* The patient must be newly prescribed CZP according to local regulations or guidelines (eg, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \>=4).
* Treatment is according to instructions in the Summary of Product Characteristics (SmPC) for patients considered by the treating physician to be reliable and capable of adhering to the observational plan (eg, able to understand and complete questionnaires).
* If a patient is participating in an ongoing investigational study, then he/she will not be able to take part in this study.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Parexel
INDUSTRY
UCB Biopharma S.P.R.L.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Cares
Role: STUDY_DIRECTOR
+1 844 599 2273 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
406
Middlesbrough, , United Kingdom
602
Brussels, , Belgium
604
Edegem, , Belgium
601
Genk, , Belgium
603
Heusy, , Belgium
53
Altenburg, , Germany
18
Bayreuth, , Germany
6
Bayreuth, , Germany
13
Berlin, , Germany
14
Berlin, , Germany
16
Berlin, , Germany
30
Berlin, , Germany
7
Berlin, , Germany
4
Burghausen, , Germany
25
Chemnitz, , Germany
50
Cottbus, , Germany
11
Dresden, , Germany
8
Düsseldorf, , Germany
36
Elmshorn, , Germany
35
Erfurt, , Germany
19
Freiburg im Breisgau, , Germany
41
Goslar, , Germany
26
Greifswald, , Germany
32
Halle, , Germany
23
Hamburg, , Germany
47
Hamburg, , Germany
1
Hanover, , Germany
44
Hanover, , Germany
42
Heidelberg, , Germany
10
Herne, , Germany
40
Hofheim am Taunus, , Germany
34
Hoyerswerda, , Germany
27
Karlsruhe, , Germany
48
Karlstadt am Main, , Germany
49
Karlstadt am Main, , Germany
21
Leipzig, , Germany
38
Leipzig, , Germany
9
Magdeburg, , Germany
29
Marktredwitz, , Germany
31
München, , Germany
43
München, , Germany
2
Naunhof, , Germany
20
Planegg, , Germany
24
Potsdam, , Germany
15
Püttlingen, , Germany
28
Saarbrücken, , Germany
51
Wuppertal, , Germany
39
Zwickau, , Germany
202
Athens, , Greece
210
Athens, , Greece
211
Athens, , Greece
212
Athens, , Greece
207
Larissa, , Greece
208
Marousi, , Greece
201
Pátrai, , Greece
203
Thessaloniki, , Greece
204
Thessaloniki, , Greece
205
Thessaloniki, , Greece
206
Thessaloniki, , Greece
504
Florence, , Italy
501
Palermo, , Italy
502
Potenza, , Italy
505
Roma, , Italy
500
Siena, , Italy
503
Verona, , Italy
116
Barcelona, , Spain
114
Bilbao, , Spain
122
Cartagena, , Spain
108
Córdoba, , Spain
118
Donostia / San Sebastian, , Spain
120
Granada, , Spain
107
León, , Spain
123
Lorca, , Spain
101
Mérida, , Spain
119
Murcia, , Spain
117
Salamanca, , Spain
121
Sant Joan Despí, , Spain
112
Tarragona, , Spain
115
Terrassa, , Spain
416
Barnsley, , United Kingdom
405
Basingstoke, , United Kingdom
401
Bath, , United Kingdom
423
Bolton, , United Kingdom
421
Christchurch, , United Kingdom
403
Hull, , United Kingdom
420
Leeds, , United Kingdom
415
Leicester, , United Kingdom
409
Liverpool, , United Kingdom
422
Llandudno, , United Kingdom
411
Luton, , United Kingdom
414
Manchester, , United Kingdom
424
North Shields, , United Kingdom
413
Norwich, , United Kingdom
410
Preston, , United Kingdom
412
Southampton, , United Kingdom
419
Stevenage, , United Kingdom
418
Sunderland, , United Kingdom
408
Torquay, , United Kingdom
407
Truro, , United Kingdom
425
Wigan, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AS0002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.